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Abstract
Background: 57.7% of the US population between the ages of 14-49 years is seropositive to antibodies for
the herpes simplex virus type 1 (HSV1). It has been concluded in studies that lysine, an essential amino acid,
inhibits the multiplication of HSV1 in cell cultures when there is high concentration of lysine in the culture
medium. Conversely, arginine, a natural amino acid is required for viral replication. At the cellular level, lysine
acts as a herpes virus inhibitor by antagonizing arginine. An effective treatment in the prevention of recurrent
HSV1 outbreaks has the potential to impact daily living. Could lysine become an effective prophylactic
treatment that reduces the recurrence rate of herpes labialis outbreaks?
Methods: An exhaustive search was conducted using Medline-OVID, CINAHL, Web of Science, Google
Scholar using the keywords: lysine, L-lysine, oral herpes simplex, herpetic stomatitis, herpes simplex, HSV-1,
herpesvirus 1, herpes labialis, prevention, and prophylactic. Relevant articles were assessed for quality using
GRADE. A search on the National Institute of Health (NIH) clinical trials site revealed no currently registered
trials, at any phase, relating to the use of L-lysine for prophylactic treatment of herpes labialis.
Results: Two randomized, double blind, placebo-controlled trials met inclusion criteria and were included in
this systematic review. The first study with 26 participants demonstrated a strong association between high
serum lysine levels and a decrease in lesion frequency suggesting that prophylactic lysine may be useful in
managing select cases of recurrent herpes labialis. The second trial with 65 participants demonstrated no
statistically significant reduction in the number of herpes labialis recurrences during the trial; however, the
results suggest that certain patients may benefit from prophylactic lysine therapy with a reduction in herpes
labialis and this requires further investigation.
Conclusion: The effects of L-lysine prophylactic therapy in suppression of herpes labialis is clear but not for
all individuals. Supplemental L-lysine taken at recommended dosages provides a prophylactic therapy benefit
to patients whose body responds to the supplementation with an increase in serum lysine levels. Treatment
effect seems to vary per person depending on serum lysine levels. The questions remaining are what is the
optimal lysine serum level to provide protection for a majority of persons from herpetic outbreaks and is it
consistently attainable with individual variables such as patient response to supplementation? L-lysine
prophylactic therapy is a cost efficient safe therapy to be considered by patients who are open to trying
alternative treatments for herpes labialis.
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Abstract   
 
Background: 57.7% of the US population between the ages of 14-49 years is seropositive to 
antibodies for the herpes simplex virus type 1 (HSV1). It has been concluded in studies that 
lysine, an essential amino acid, inhibits the multiplication of HSV1 in cell cultures when there is 
high concentration of lysine in the culture medium. Conversely, arginine, a natural amino acid is 
required for viral replication. At the cellular level, lysine acts as a herpes virus inhibitor by 
antagonizing arginine. An effective treatment in the prevention of recurrent HSV1 outbreaks has 
the potential to impact daily living. Could lysine become an effective prophylactic treatment that 
reduces the recurrence rate of herpes labialis outbreaks? 
 
Methods: An exhaustive search was conducted using Medline-OVID, CINAHL, Web of 
Science, Google Scholar using the keywords: lysine, L-lysine, oral herpes simplex, herpetic 
stomatitis, herpes simplex, HSV-1, herpesvirus 1, herpes labialis, prevention, and prophylactic.  
Relevant articles were assessed for quality using GRADE. A search on the National Institute of 
Health (NIH) clinical trials site revealed no currently registered trials, at any phase, relating to 
the use of L-lysine for prophylactic treatment of herpes labialis. 
 
Results: Two randomized, double blind, placebo-controlled trials met inclusion criteria and were 
included in this systematic review. The first study with 26 participants demonstrated a strong 
association between high serum lysine levels and a decrease in lesion frequency suggesting that 
prophylactic lysine may be useful in managing select cases of recurrent herpes labialis. The 
second trial with 65 participants demonstrated no statistically significant reduction in the number 
of herpes labialis recurrences during the trial; however, the results suggest that certain patients 
may benefit from prophylactic lysine therapy with a reduction in herpes labialis and this requires 
further investigation.  
 
Conclusion: The effects of L-lysine prophylactic therapy in suppression of herpes labialis is 
clear but not for all individuals. Supplemental L-lysine taken at recommended dosages provides 
a prophylactic therapy benefit to patients whose body responds to the supplementation with an 
increase in serum lysine levels. Treatment effect seems to vary per person depending on serum 
lysine levels. The questions remaining are what is the optimal lysine serum level to provide 
protection for a majority of persons from herpetic outbreaks and is it consistently attainable with 
individual variables such as patient response to supplementation? L-lysine prophylactic therapy 
is a cost efficient safe therapy to be considered by patients who are open to trying alternative 
treatments for herpes labialis.  
 
Keywords: Lysine, herpes labialis, prophylactic, herpes simplex, human 
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L-Lysine Hydrochloride: An Alternative Prophylactic Therapy  
Reducing the Recurrence Rate of Herpes Labialis 
 
BACKGROUND 
 Of the US population, 57.7% of individuals between the ages of 14-49 years are 
seropositive for antibodies to herpes simplex virus type 1 (HSV1). 1 Herpes simplex virus -1 is 
part of the herpesviridae family, a large family of DNA viruses that are known to instigate 
recurring infections. The lingering latent characteristic of HSV1 and its ability to reactivate, 
inducing recurrent infections such as herpes labialis, invoke distress and visual sores in the 
effected population. These lesions along the vermillion boarder of the lip contain infectious viral 
particles from the viral shedding of the herpes virus, can be very painful and potentially 
disfiguring. 2 The repetitive recurrence of these lesions can induce depression, missed work or 
life experiences from the fear of rejection, and possibly even isolation from a fear of being found 
out to have “a cold sore”. 3  
 There are no vaccines to prevent the primary herpes simplex infection in patients. Until a 
vaccine can be found, the therapies available to treat the HSV infections focus on decreasing the 
number of days in an outbreak, severity of the lesions and on preventing outbreaks from 
occurring altogether.  Taking medication to prevent lesions from recurring (prophylactic therapy) 
is a top priority to decrease the suffering of individuals. Available antiviral agents approved by 
the FDA for chronic suppressive therapy of herpes labials include acyclovir and valacyclovir. 
These two drugs interfere with the synthesis of viral DNA. 4 Antiviral drugs cannot eradicate the 
virus from its dormant (latent) state within the nerve cells—neural ganglia that supply sensation 
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to the skin. The cost consideration and the side effects of these antiviral drugs must be included 
in decision making when considering the use of them chronically. 
 Amino acids, such as lysine and arginine, are organic compounds that make up proteins. 
Studies have demonstrated that arginine, a natural amino acid building block, is required for 
HSV1 replication. 5 HSV1 is highly dependent on arginine. 6 It has been determined that HSV1 
synthesizes proteins higher in arginine content than lysine. 7 Lysine, an essential amino acid, is 
involved in making proteins and metabolizing carbohydrates and fatty acids. Lysine inhibits the 
multiplication of HSV1 in cell cultures when there is high concentration of lysine in the culture 
medium. 6 Lysine is not synthesized in humans; therefore, it must be ingested as L-lysine or 
contained within ingested proteins. Dietary sources of lysine include meat, cheese, yogurt, 
brewer's yeast, legumes, and wheat germ. 8 Lysine, a herpes virus inhibitor, antagonizes arginine9 
by way of the following five mechanisms. Lysine functions as an antimetabolite of arginine. 
Lysine competes with arginine for reabsorption in the renal tubules thereby increasing arginine 
excretion in urine. Lysine also competes with arginine for transport into cells and at absorption 
sites in the intestines. If there is excess concentration of lysine in the gut, than absorption of 
arginine is decreased. Lastly, lysine induces enzyme arginiase, which degrades arginine. 
 An effective, safe, and inexpensive long-term prevention therapy of recurrent HSV1 
outbreaks has the potential to impact daily living. Could lysine become a daily oral supplement 
that reduces the recurrence rate of herpes labialis outbreaks, consequently becoming an effective 
prophylactic therapy? 
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METHODS 
 An exhaustive literature search was conducted using Medline-OVID, CINAHL, Web of 
Science, Google Scholar. The following search keywords were utilized: lysine, L-lysine, oral 
herpes simplex, herpetic stomatitis, herpes simplex, HSV-1, herpesvirus 1, herpes labialis, 
prevention, and prophylactic.  The search was narrowed to include only English language articles 
and research on humans. Articles evaluating L-lysine as a prophylactic agent for herpes labialis 
were included. The bibliographies of the articles were further searched for relevant sources.  
Trials that did not separate the data between herpes labialis and genital herpes were excluded. 
Review articles and editorials were used for background research. Relevant articles were 
assessed for quality using the Grading of Recommendations, Assessment, Development and 
Evaluation (GRADE). 10 A search on the National Institute of Health (NIH) clinical trials site 
revealed no currently registered trials, at any phase, relating to the use of L-lysine for 
prophylactic treatment of herpes labialis. 
RESULTS 
 Initial results of the search yielded 301 articles for review. After filtering the articles, 
weeding out non-human trials, a total of 8 articles were reviewed further for relevancy. Two 
additional articles were located through the references. Of these 10 articles, three randomized 
control trials (RCT) were excluded due to the inclusion of patients with genital herpes where the 
data collected did not differentiate between orolabial and genital lesions. Four articles were 
secondary analysis reviews and one was descriptive research— a case report, which was 
excluded due to low GRADE criteria and the inclusion of genital lesions. A total of two articles 
fit inclusion criteria and both are randomized control trials. 11,12 See Table I. 
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Thein and Hurt 
 This randomized control trial11 examined the host environment to determine the efficacy 
of long-term prophylactic L-lysine supplementation for treating the clinical symptoms of 
recurrent herpes simplex labialis in a double-blind, placebo-controlled, crossover study. The 52-
week trial had an uninterrupted crossover from lysine treatment to placebo or placebo to lysine at 
the 6-month mark. An identical-appearing cellulose placebo was used as the control. The trial 
enrolled study participants, all otherwise healthy volunteers, with at least three circumoral herpes 
lesions in the preceding 12 months. Frequency of recurrences ranged from 4-16 per year (median 
number: 12 episodes in the past year). Twenty-six participants included in the statistical analysis 
were comprised of 23 females and three males, between the ages of 8-50 years (median 29 
years). The primary outcome was the frequency of herpes simplex recurrences during a 52-week 
prophylactic treatment with L-lysine and placebo. Patients were directed to contact the authors at 
the appearance of a lesion for a positive diagnosis to be made on the basis of standard cytologic 
criteria. 14 And patients were given journals, at the initial visit and at the 6-month appointment, to 
record pertinent information regarding outbreaks. A secondary outcome was the individual 
serum levels of lysine and arginine and the lysine:arginine ratio (L/A). 11 Serum samples were 
collected at scheduled intervals: initial visit, 6 months, and 12 months. At the conclusion of the 
52-week trial, all serum samples were prepared for analysis and examined in an automated 
amino acid analyzer. Student’s t-tests were used to determine any significance between the two 
sample means.11 
 Eligibility criteria included at least three circumoral herpes simplex lesions 12 months 
prior in otherwise healthy individuals. Participants’ medical anomalies were recorded on medical 
health history questionnaires. The participants were randomly divided into two groups at the 
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onset of the trial. Group A: 15 members began with lysine tablets. Group B: 11 members started 
with cellulose placebo. No significant difference was noted between the two treatment groups in 
the two 6-month periods immediately preceding the study in regards to frequency of lesions, 
serum lysine and arginine levels, or the lysine:arginine ratio. There was insignificant difference 
in the health profiles between the two groups. The number and kind of medical problems 
reported by the participants appeared consistent with that of the general population of similar 
age.11 
The patients were given a journal on initial visit along with tablets containing 500 mg L-
lysine monohydrochloride or cellulose placebo and instructed to take two tablets every morning 
before breakfast, a daily dose of 1000 mg. Nuts, seeds, chocolate, and cereal products are foods 
high in arginine content12. These food products, high in dietary arginine, were recommended for 
reduction. Crossover occurred at 6 months with a 6-month supply of tablets distributed to the 
participants. A closing interview was conducted to obtain information from each participant 
regarding the experiment. 11  
 Results suggest that prophylactic lysine may be useful in managing selected cases of 
recurrent herpes simplex labialis if serum levels can be maintained at adequate concentrations. 11 
When a person’s serum lysine concentration exceeded 165 nmol/ml, it yielded a significant 
decrease in recurrent lesions (p < 0.05).  There was also a corresponding increase in frequency 
rate of herpetic lesions as serum lysine concentration levels fell below 165 nmol/ml. At the end 
of the first 6-month period, the frequency of lesions in those subjects given lysine did not differ 
significantly from the frequency in those given placebo. See Table II. In contrast, the subjects 
who began taking lysine during the second 6-month test period reported a significantly fewer 
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lesions than those who had reverted to placebo (p< 0.05). Between months 6-12 subjects in 
Group B who were put on lysine supplementation demonstrated a significant greater blood lysine 
concentration than those in Group A whom lysine was not supplemented (p< 0.01). Similarly, 
during the second 6-month test period, when Group A was taken off the lysine supplementation, 
there was a significant increase in the frequency of lesions (p< 0.01) while Patients in Group B, 
in which lysine was added at the 6-month mark, reported a significant decrease in lesion 
recurrence (p <0.01). In addition, there was a significant decrease in blood lysine levels between 
the first 6-months test period and the second in group A patients (p <0.05).11 
 The authors found that limitations to this study included the puzzling aspect of the results 
pertaining to the lack of statistical significance obtained during the first 6-months of the trial. 
Certain persons in the placebo group may have been supplementing their dietary intake of lysine 
unknowingly and consequently raising their serum lysine levels in excess of  >165 nmol/ml 
thereby having a therapeutic effect without the L-lysine monohydrochloride treatment. Another 
limitation is the fact that some participants appeared to have different capacities to absorb lysine 
than others.  The authors postulate on a possible lysine transport defect across intestinal villi or 
in target cells, other metabolic products competing for same transport receptors or a higher than 
normal lysine concentration needed to have an inhibitory effect in persons with recurrent 
herpetic lesions. They also discussed the unquestioned clinical value in determining the specific 
quantitative figures regarding the blood levels of lysine needed to reduce recurrent lesions in 
future research.11 
Milman et al  
  This randomized control trial,13 evaluating the prophylactic effect of L-lysine 
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monohydrochloride on recurrent herpes simplex labialis, was a double-blind, placebo-controlled, 
crossover study. The 24-week trial had an uninterrupted crossover from lysine treatment to 
placebo or placebo to lysine at the 12-week mark. Every second patient started with lysine and 
alternate patients with placebo. The trial enrolled 79 initial study participants all otherwise 
healthy volunteers with at least three perioral and/or prolabial herpes simplex episodes in the 
preceding 12 months. Of the 79, 14 did not complete the investigation and were excluded. Final 
material comprised 65 patients: 52 females and 13 males, all of whom are between the ages of 
16-73 years (median 36 years). The primary outcome was the number of herpes simplex 
recurrences during a 12-week prophylactic treatment with L-lysine or placebo.13 
A secondary outcome was the duration of the outbreak. The start of an episode was 
defined as the appearance of burning, itching, tingling (prodrome) and/or erythema. The end of 
an episode was noted when the surface crust of the lesion had been discharged and all discomfort 
and swelling resolved, residual erythema could be present. Another secondary outcome was the 
classification of the lesion when judged to be at its worst according to the following scale: (1) 
itching, burning, tingling, or tenderness but no visible lesion; (2) erythema with induration 
(papule) and/or vesicles without exudate; (3) vesicles with exudation and/or crust, lesion 15 mm 
or less, measured along the largest diameter; (4) vesicles with exudation and/or crust, lesions 
greater than 15 mm.13 
 Eligibility criteria of at least three perioral and/or prolabial herpes simplex episodes in 
preceding 12 months was verified by the observation of lesions and the remaining cases upon a 
thorough history. The patients were given a questionnaire on initial visit with tablets containing 
500 mg L-lysine monohydrochloride or starch powder (placebo) and instructed to take one tablet 
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by mouth twice daily (BID); daily dose of 1000 mg. The patients were directed to record the 
duration and course of the herpes simplex recurrences plus classify the lesions.  Every four 
weeks the questionnaires were returned along with residual tablets and new questionnaires and 
tablets were sent to the study participants.13 
 A significantly greater number of participants were recurrence-free during lysine than 
during placebo treatment. See Table III. Fourteen patients had no recurrences during lysine 
treatment but did have recurrence during placebo treatment. Four patients starting with lysine 
had no recurrences during either treatment. Four patients had no recurrence during placebo but 
recurrence during treatment with lysine. This difference is at the limit of significance (p=0.05). 13 
Looking at Table IV, none of the differences in effect of placebo or L-lysine were statistically 
significant. What is discerned from Table IV is there is a 33.3% drop in recurrences when 
patients switched from placebo (66 total recurrences) to L-lysine treatment (46 total recurrences).  
In patients initially treated with placebo there was a reduction in recurrence during subsequent 
lysine treatment. Also, patients initially treated with lysine had a lower number of recurrences on 
placebo treatment (38 total recurrences) than had patients initially treated with placebo (66 total 
recurrences). The authors observed that a possible prophylactic long-term effect of lysine could 
be postulated from these numbers. Looking at the secondary outcome of rate of healing and the 
appearance of the recorded herpes lesions at their worst, there was no significant difference 
between L-lysine and placebo treatment series. 13  
 The authors found that limitations to this study included a large placebo response, short 
observation period, and complicated interpretation of results. They also discussed the 
investigative problems arising from the inter- and intra-individual variations in the frequency and 
 15 
course of recurrent herpes labialis when evaluating the prophylactic treatment of lysine. The 
author recommended large patient population, long observation periods, and emphasized the 
absolute necessity of double-blind controlled trials. 13  
DISCUSSION 
 Oral lysine supplementation can reduce the recurrence rate of herpes labialis outbreaks in 
select cases when taken as a prophylaxis treatment. The Thein and Hurt study11 ran Student’s t-
test to look at the correlations between patient’s serum lysine levels and the number of lesion 
recurrences. Results from their study population indicated that when a person’s serum lysine 
concentration exceeded 165 nmol/ml, there was a corresponding significant decrease in recurrent 
lesions (p < 0.05). 11 Likewise, when the serum concentration dropped below 165 nmol/ml lesion 
frequency increased significantly. 11 Whether the lysine serum concentration is from food sources 
containing the amino acid lysine or supplemental L-lysine tablets 1000 mg/day, it is the 
increased serum concentration in excess of 165 nmol/ml that decreases the frequency of herpes 
labialis. Although, the Milman et al13 trial showed no significant prophylactic effect of lysine 
therapy on the recurrence rate and duration of herpes simplex labialis the research does suggest 
that certain patients may benefit from the treatment. Significantly more patients were recurrence 
free during lysine than placebo treatment. There were eighteen patients who had no recurrences 
during lysine treatment, while fourteen of those eighteen patients had recurrences during placebo 
treatment. 13 This correlates with past research that lysine is a suppressant not a curative 
treatment once viral replication has begun within an oral lesion.6 
 Six studies11,13-17 were conducted between 1980-1987 on prophylactic therapy of 
recurrent herpes simplex virus with L-lysine. Four of the studies14-17 are not included in this 
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review because they included data on genital herpetic lesions. All but one of these studies 
showed favorable results for the use of L-lysine in the prevention of HSV outbreaks. Even 
though these studies did not meet inclusion criteria, they should not be ignored. The most recent 
study conducted in 1987 by Griffith et al17 found statistical significance of L-lysine 
monohydrochloride therapy (1,000 mg L-lysine per dose, three times a day for 6 months) with an 
average 2.4 (p >0.05) less HSV recurrences, symptoms were significantly (p <0.05) diminished 
in severity and healing time was significantly reduced (p <0.05). 17  
 While the studies11,13 demonstrated that some patients benefit from lysine prophylaxis in 
recurrent herpes simplex labialis, they both have limitations. The major limitations detected 
include length of study, study size, and risk of bias specifically attrition bias, detection bias, 
performance bias, and carryover effect. Milman et al13 conducted a 24-week trial with 79 
participants. There were 14 participants who did not complete the study and were excluded. The 
authors do not address the 17.7% withdrawal from the study leading to incomplete outcome data. 
Only 12-weeks of the 24-week Milman et al13 trial had the patients on L-lysine 
monohydrochloride therapy. The short therapy window makes it difficult to base future treatment 
protocols off this study. Thein and Hurt11 investigated lysine therapy for 52-weeks with the 
crossover at 6-months. Thein and Hurt11 had an impressive length of study in comparison to all 
previous studies addressing lysine as a prophylactic treatment in humans but failed to capture a 
large sample population, only 26 participants (three males, twenty-three females). Thein and 
Hurt11 efficiently documented their data into a table showing herpetic lesion frequency per 
patient. See Table V. This empowered the reader to realize that patients had dramatic decreases 
in herpetic lesions with treatment. It would have been beneficial to see a correlation between the 
lysine serum levels and lesions per patient. Milman et al13 aggregated the number of herpetic 
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lesion recurrences only by treatment group, failing to breakdown the data by lesions per 
individual before and during the study. This makes it impossible to discern which participants 
had dramatic decreases in HSV1 outbreaks and who were the outliers that did not respond to 
treatment. 
 Milman et al13 collected data on recurrent herpes lesions with a questionnaire. This can 
lead to detection bias and is apparent due to a lack of definitive diagnosis of the lesions: 
subjective accounting of evidence from the participants without standard criteria. Thein and 
Hurt11based their positive diagnosis of recurrent herpes simplex labialis off standard cytologic 
criteria.18 Thein and Hurt11addressed a risk of performance bias regarding the possible diet 
supplementation with lysine from sources other than the experimental tablets provided in the 
placebo group. Patients inadvertently raising their serum lysine levels with the ingestion of foods 
high in the amino acid, lysine. Regardless, Thein and Hurt11 conclude that if lysine levels exceed 
165 nmol/ml lesion recurrence significantly declines. The participants in this study11 were also 
asked to limit the intake of arginine containing foods. It was discovered that most participants 
did not adhere to this recommendation. Until this variable can be controlled, researchers will not 
be able to determine if it is an inadequacy of lysine or an excess in arginine consumption that 
leads to the preferential environment for viral replication.11 
 The final risk of bias to be addressed is the carryover effect in crossover studies. Both 
studies11,13 had the two groups of patients switch from lysine therapy to placebo or from placebo 
to lysine therapy. In the Milman et al13 study, patients initially treated with lysine had a lower 
number of recurrences on placebo treatment than has patients initially treated with placebo. This 
could be attributed to a prophylactic long-term effect of lysine but the authors demonstrate that 
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the data does not support this interpretation. In patients with serum levels in excess of 165 
nmol/ml there is a significant decline in lesion recurrences. 11 Although it is possible that there 
was a carryover effect in the Thein and Hurt11 study, the potential bias does not skew these 
favorable end results.  
 Moving forward, further studies need to be done on this topic in order to truly evaluate 
the quantitative figures regarding the blood levels of lysine needed to reduce the recurrence of 
herpes labialis and to determine the effect of arginine ingestion that could be sabotaging the 
increased L-lysine supplementation. The results from the Thein and Hurt study11 hold a moderate 
GRADE10 with significant findings that connect serum lysine levels with herpetic lesion. 
Because of the overall low quality of evidence of the Milman et al study,13 the results are not 
reliable to change or alter practice decisions. A larger, randomized control trial, focusing on 
finding a relative range of lysine serum values in correlation with arginine dietary restrictions 
could lead to better results that support the prophylactic use of L-lysine.  
 L-lysine hydrochloride, an amino acid building block for protein, is available as an over-
the-counter dietary supplement at low cost to consumers: 1000mg/ day works out to $0.07/day, 
$26.22/year. 19 The price tag for yearly prophylaxis with generic acyclovir is approximately 
$274.00 and valacyclovir approximately $1,080.00. 19 Contraindications for lysine 
supplementation are patients with renal disease or hepatic impairment due to catabolism taking 
place in the liver and potential inability to eliminate large amounts of nitrogen produced upon the 
breakdown of supplemented amino acids. 20 Interactions with lysine supplementation include 
calcium with the possible side effects of increased gallstones and aminoglycoside antibiotics, 
which could increase the risk of nephrotoxicity.21 
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 Side effects of the antiviral drugs acyclovir and valacyclovir are extensive and include 
headache, neutropenia, elevated liver enzymes, nausea, abdominal pain, and malaise. Warnings 
include hypersensitivity, thrombolic thrombocytopenia purpura (TTP), hemolytic uremic 
syndrome (HUS), acute renal failure (ARF), and central nervous system 
involvement.22,23Acyclovir has a safer profile and is more cost efficient than valacyclovir but 
both cost exceedingly more than L-lysine hydrochloride and L-lysine has a safer profile.  
CONCLUSION 
 The effects of L-lysine prophylactic therapy in suppression of herpes labialis is clear but 
not for all individuals. There are many variables such as individual diets containing lysine and 
arginine, the personal ability to absorb or utilize L-lysine, and manipulating the correlation 
between L-lysine supplementation and the serum lysine concentration. A prophylactic treatment 
of 1000 mg L-lysine per day dramatically reduced the recurrence rate when a person’s serum 
lysine concentration exceeded 165 nmol/ml but as Thein and Hurt11 state, this is the threshold 
value for their particular sample population which may not be the level needed to provide 
protection from herpetic outbreaks in all persons. The question remaining is, what is the optimal 
lysine serum level to provide protection for the majority of persons from herpetic outbreaks and 
is it consistently attainable with life variables?  
 Supplemental L-lysine taken at recommended dosages provides a prophylactic therapy 
benefit to patients whose bodies responds to the supplementation with an increase in serum 
lysine levels.  It is a safe therapy to consider for patients without renal disease who are looking 
for a cost efficient treatment option for recurrent herpes labialis. A large, randomized control 
trial, focusing on finding a relative range of lysine serum values in correlation with lysine 
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supplementation and arginine dietary restrictions could lead to more consistent results. This 
study needs to have statistical data, broken down per patient that can help to determine the 
population that will respond to L-lysine treatment. A safe cost effective treatment option for 
patients with herpes labialis will make a difference in daily living and decrease the suffering of 
patients with frequent herpes labialis outbreaks. 
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Table I. Characteristics of Reviewed Studies 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a Risk of Recall bias and risk of attrition bias in the Milman et al study  
b Risk of carryover effect in the Thein and Hurt study  
c Outcomes of interest are underpowered in the Milman et al study 
d Small sample size and length of study in the Milman et al study and  
e small sample size in the Thein and Hurt study  
f No reporting of prognostic balance in the Milman et al study 
 
 
Table II. Thein and Hurt11 
* Indicates a statistically significant difference between the two groups (p ≤ 0.05) 
± Values indicate standard deviation 
 
 
 
Quality Assessment  
Importance  Downgrade Criteria 
Quality 
Study Design Limitations Indirectness Imprecision Inconsistency Publication bias likely 
Frequency of Recurrent Herpes Labialis   
Thein and Hurt11  
& Milman et al13  
2 
RCT 
 Serious 
limitationsa, b 
No serious 
indirectnessc 
Serious 
imprecisiond, e 
No serious 
inconsistenciesf 
No bias 
likely Moderate Critical 
Duration of Outbreak   
Milman et al13 1 RCT 
Serious 
limitationsa 
No serious 
indirectnessc 
Serious 
imprecisiond 
No serious 
inconsistenciesf 
No bias 
likely Low Important 
Classification of Lesion at its Worst   
Milman et al13 1 RCT 
Serious 
limitationsa 
No serious 
indirectnessc 
Serious 
imprecisiond 
No serious 
inconsistenciesf 
No bias 
likely Low Important  
Serum Levels of Lysine and Arginine   
 
Thein and Hurt11 
1 
RCT 
No serious 
limitations 
No serious 
indirectness 
Serious 
imprecisione 
No serious 
inconsistencies 
No bias 
likely Moderate Less 
Serum Lysine:Arginine Ratio   
Thein and Hurt11 1 RCT 
No serious 
limitations 
No serious 
indirectness 
Serious 
imprecisione 
No serious 
inconsistencies 
No bias 
likely Moderate Less 
Student’s t-test of the significance of the difference between two sample means 
 Baseline Test Period 1 
(0-6 months) 
Test Period 2 
(6-12 months) 
 A B A B A B 
Frequency (X) 
 
4.9 
± 1.49 
4.05 
± 2.25 
2.60 
± 2.58 
2.82 
± 2.37 
2.93* 
± 2.43 
1.18* 
± 1.19 
Serum lysine concentration 
(nmol/ml)  (X) 
173.78 
± 53.40 
175.17 
± 42.45 
197.05 
± 30.26 
190.48 
± 34.36 
172.92* 
± 39.61 
224.92* 
± 79.11 
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Table III. Milman et al13 
 
 
 
 
 
 
 
 
 
Table IV. Milman et al13 
 
 
 
 
 
 
 
 
 
 
 
 Table V. Thein and Hurt11 
 
Recurrence Pattern of herpes simplex in 65 patients during prophylactic treatment 
with lysine (L) and placebo (P) in a crossover study 
Outcomes 
Patients 
starting with L 
(n=31) 
Patients 
starting with P 
(n=34) 
Total 
(n=65) 
Patients having 
no recurrence during L treatment 
(but recurrences during P treatment) 
5 9 14 
Patients having 
no recurrence during P treatment 
(but recurrences during L treatment) 
2 2 4 P=0.05 
Patients having recurrence during  
Both L and P treatment 20 23 43 
Patients having recurrence no during  
Both L and P treatment 4 0 4 
Number of herpes simplex recurrences during a 12-week prophylactic treatment 
with lysine (L) and placebo (P) in a crossover study 
Outcomes 
Patients 
starting with L 
(n=31) 
Patients 
starting with P 
(n=34) 
Total 
(n=65) 
Total no. of recurrences during 
L treatment 45 46 91 
Median and range 1 (0-4) 1 (0-6) 1 (0-6) 
Total no. of recurrences during 
P treatment 38 66 104 
Median and range 1 (0-4) 2 (0-6) 1 (0-6) 
Herpetic lesion frequency (number of episodes) 
Patients 12-month  
period prior to study 
Experimental period  
0-6 months 
Experimental period  
6-12 month 
Group A (Began with lysine tablets 0-6 months then switched to placebo at 6 months) 
1 >12 1 1 
2 >12 1 1 
3 12 2 2 
4 12 1 1 
5 12 8 5 
6 >12 6 6 
7 8 0 0 
8 >4 0 2 
9 >6 3 4 
10 >10 7 5 
11 >6 3 2 
12 5 1 0 
13 >12 0 1 
14 >12 1 1 
15 >12 5 8 
Group B (Began with placebo 0-6 months then switched to placebo at 6 months) 
16 >4 2 0 
17 >6 0 2 
18 4 3 0 
19 >3 1 1 
20 >16 7 3 
21 >12 2 2 
22 12 2 2 
23 >12 7 3 
24 >12 5 0 
25 >3 2 0 
26 5 0 0 
